 CAMBRIDGE, Mass., Jan. 19, 2021 GLOBE NEWSWIRE -- TCR2 Therapeutics Inc. Nasdaq: TCRR TCR2 or the Company, a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced that it has commenced an underwritten public offering of 125,000,000 of shares of its common stock. TCR2 also intends to grant the underwriters a 30-day option to purchase up to an additional 18,750,000 of shares of common stock. All of the shares in the proposed offering are to be sold by TCR2. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the proposed offering may be completed, or as to the actual size or terms of the proposed offering. 